Navigation Links
SpineSmith Adds Talented Scientist to Research and Development Team
Date:1/17/2012

AUSTIN, Texas, Jan. 17, 2012 /PRNewswire/ -- SpineSmith, a Celling Biosciences company that designs, develops and markets innovative technologies in the field of regenerative medicine, is pleased to announce the addition of Dr. Matthew Murphy to its team of PhDs.

Dr. Murphy joins SpineSmith in the position of Senior Scientist and will design and implement new strategies for the isolation and application of autologous stem cells for spine, orthopedics, and cardiovascular therapies.

"We are very happy to have Dr. Murphy join our team of PhDs. His expertise in biomaterials and cell technology brings SpineSmith an important opportunity to expand our research especially as we continue to grow as a company," said Vice President of Cell Therapies, Dr. Ted Sand.

Previously, Murphy was a senior researcher at Methodist Hospital Research Institute in Houston, Texas, where he focused on the combination of adult stem cells and biomaterials for regenerative medical applications in orthopedics, spine, pancreatic, and soft tissue repair.

Murphy holds a PhD in Bioengineering from Rice University and a B.S. in Chemical Engineering from The University of Texas at Austin. At Rice, he researched novel biomaterials for bone and cartilage regeneration and developed targeted drug delivery strategies. He also worked at NASA on the design of new spacesuits for travel to the moon and Mars as part of the Constellation Program.

He then joined the laboratory of Dr. Paul Simmons at UT Health Science Center at Houston where he investigated adult stem cells harvested from bone marrow, cortical bone, and adipose tissues. He has authored twelve peer-reviewed publications and two textbook chapters related to tissue engineering and drug delivery.

"I'm excited to help expand Celling Biosciences' therapeutic treatments using adult stem cells," said Dr. Murphy. "Using optimized biomaterials, natural enhancers such as PRP and extracellular matrix proteins, and effective delivery systems, we can maximize stem cell retention and bioactivity. Regenerative therapies are the future and a key to personalized medicine."

About SpineSmith LLC- A Celling Biosciences Company

SpineSmith Partners LP designs, develops and markets implants and biologics for surgical fixation, correction and tissue regeneration of the spine. SpineSmith utilizes a collaborative approach between scientists, engineers and spine surgeons. Our unique approach gives spine surgeons the ability to directly impact the direction of our product portfolio, ensuring applicability and achieving the highest standards of patient care.  For more information please visit:  www.spinesmithusa.com.  

 

 


'/>"/>
SOURCE SpineSmith LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SpineSmith Successful in VisuALIF Alpha Launch
2. Pioneer® Surgical Technology, Inc. Announces Agreement to Acquire Exclusive Access to the Cequence™ Cervical Plate System From SpineSmith, LP
3. SpineSmith Partners Announces FDA Clearance and Product Launch of VisuALIF Interbody Fusion Device at North American Spine Society Annual Meeting
4. SpineSmith Partners and Celling Technologies Hire New VP of Research and Development
5. SpineSmith Partners to Present at 3rd Annual Stem Cell Summit
6. New AquaLab Vapor Sorption Analyzer Puts Isotherm Technology Within Financial Reach of Food and Pharmaceutical Scientists
7. Do You See What I See: Scientists Model Brain Structure To Help Computers Recognize Objects
8. No European Scientists Left by 2020?
9. Life Technologies Makes Fluorescence Microscopy Accessible to All Scientists
10. American Skin Association Honors Leading Physicians and Scientists; Journalist Deborah Norville
11. Over 400 Graduate Level Scientists to Attend Virtual Job Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... AccuGenomics, Inc., a diagnostic company based in ... the company has provided an AccuKit to the HIV ... Chapel Hill and to Qura Therapeutics for evaluation in ... HIV reservoir and viral expression in human CD4+ T ... Center is a joint initiative between the University of ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... More than 20,000 pairs of ... Congo (DRC) thanks to an ambitious venture that conjoined the passions of an NBA ... support of the Liberty community. These shoes will save lives from the rampant infections ...
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today announces the launch ... lifestyles and highlighting the importance of proactive eye and ear health. The campaign ... latest innovations in hearing aid technology. , In this issue, the National ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... handling handheld devices. Through an educational webinar, they will present the line of ... chance to learn how easy you can automate everyday pipetting tasks. , Ideal ...
(Date:8/18/2017)... ... 2017 , ... Radabaugh & Associates, a family managed agency ... West Virginia, is embarking on a cooperative charity effort with the Chestnut Mountain ... Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for young men offering ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Brian Gifford Agency, an ... is campaigning in support of Campagna Academy in a charity drive to provide for ... Boys’ Town of Indiana,” Campagna Academy is a nonprofit organization that has offered critical ...
Breaking Medicine News(10 mins):